Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.

Kristina Aaltonen, Ann Rosendahl, Hans Olsson, Per Malmström, Linda Werner Hartman, Mårten Fernö

Research output: Contribution to journalArticlepeer-review

16 Citations (SciVal)
131 Downloads (Pure)

Abstract

Resistance towards endocrine therapy is a great concern in breast cancer treatment and may partly be explained by the activation of compensatory signaling pathways. The aim of the present study was to investigate if the insulin-like growth factor-1 receptor (IGF1R) signaling pathway was activated or deregulated in breast cancer patients and to explore if any of the markers were prognostic, with or without adjuvant tamoxifen. This signaling pathway has been suggested to cause estrogen independent cell growth and thus contribute to resistance to endocrine treatment in estrogen receptor (ER) positive breast cancer.
Original languageEnglish
Article number794
JournalBMC Cancer
Volume14
DOIs
Publication statusPublished - 2014

Subject classification (UKÄ)

  • Cancer and Oncology

Fingerprint

Dive into the research topics of 'Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.'. Together they form a unique fingerprint.

Cite this